• Entest Turns to Bioinformatics to Discover Therapeutics, Biomarkers for Lung Disease

    Updated: 2010-03-15 19:12:57
    , Search Home News GenomeWeb Daily News BioArray News BioInform In Sequence PCR Insider PGx Reporter ProteoMonitor RNAi News Magazine Blog The Daily Scan Informatics Iron The Sample Careers Job Listings Log in or Register Friday , March 19, 2010 Arrays Bioregionnews Biotechtransferweek Cbanews DxPGx Informatics PCR Sample Prep Proteomics RNAi Sequencing Home News Entest Turns to Bioinformatics to Discover Therapeutics , Biomarkers for Lung Disease March 15, 2010 Email Printer-friendly version The firm's bioinformatics-based approach will integrate existing and new data , including omics information about chronic obstructive pulmonary disease . Full-text access for registered users . only Existing users login here New to GenomeWeb Register quickly here for free . access Related Stories Congenital Cardiac Union March 1, 2010 Genome Technology Lilly , Merck , Pfizer Agree to Share Pre-Competitive Genomics Data on Lung , Gastric Cancers in Asia February 24, 2010 Pharmacogenomics Reporter Pfizer Taps Sage Bionetworks to Build Cancer Models for Drug Discovery , Development January 15, 2010 BioInform Vanderbilt University Launches BioVU , a DNA Data Resource to Electronic Medical Records

  • W3C Group Plans Ontology for Translational Medicine to Help Bridge Drug Discovery Phases

    Updated: 2010-03-12 18:20:04
    Search Home News GenomeWeb Daily News BioArray News BioInform In Sequence PCR Insider PGx Reporter ProteoMonitor RNAi News Magazine Blog The Daily Scan Informatics Iron The Sample Careers Job Listings Log in or Register Friday , March 19, 2010 Arrays Bioregionnews Biotechtransferweek Cbanews DxPGx Informatics PCR Sample Prep Proteomics RNAi Sequencing Home News BioInform W3C Group Plans Ontology for Translational Medicine to Help Bridge Drug Discovery Phases March 12, 2010 Type size : Email Printer-friendly version RSS Feed View on one page The World Wide Web Consortium's Health Care and Life Sciences Interest Group is plotting a semantic course to help find ways for pharma to communicate across drug discovery and development phases . Full-text access for premium subscribers . only Existing premium subscribers login here New to GenomeWeb Register quickly here 1 2 next last Related Stories Slowly Maturing , Semantic Web Technologies Reach Pilot Project Stage in Pharma March 5, 2010 BioInform Tear Down This Firewall : Pharma Scientists Call for a Pre-competitive Approach to Bioinformatics September 4, 2009 BioInform BioDiscovery Turns to the Cloud to Support Collaborative Copy Number

  • Pocketing $3.7M, Eureka Touts Informatics as Differentiator in Sequencing Services, Microorganism Detection

    Updated: 2010-03-12 18:19:59
    , , Search Home News GenomeWeb Daily News BioArray News BioInform In Sequence PCR Insider PGx Reporter ProteoMonitor RNAi News Magazine Blog The Daily Scan Informatics Iron The Sample Careers Job Listings Log in or Register Friday , March 19, 2010 Arrays Bioregionnews Biotechtransferweek Cbanews DxPGx Informatics PCR Sample Prep Proteomics RNAi Sequencing Home News BioInform Pocketing 3.7M , Eureka Touts Informatics as Differentiator in Sequencing Services , Microorganism Detection March 12, 2010 Type size : Email Printer-friendly version RSS Feed Eureka Genomics has a two-pronged business model that involves sequencing services and internal discovery projects to identify novel disease-associated microorganisms . Underlying this hybrid model is a portfolio of proprietary bioinformatics tools that the company licensed in 2006 from the University of . Houston Full-text access for premium subscribers . only Existing premium subscribers login here New to GenomeWeb Register quickly here Related Stories Wash U to Use 14M ARRA Grant to Double Size , Capacity of Genomics Data Center March 12, 2010 BioInform PacBio Teams with Sample Prep , Informatics Firms to Develop Products and Services

  • Computational siRNA Design Considering Alternative Splicing

    Updated: 2010-03-11 12:39:06
    RNA interference (RNAi) with small interfering RNA (siRNA) has become a powerful tool in functional and medical genomic research through directed post-transcriptional gene silencing. In order to apply RNAi technique to eukaryotic organisms, where frequent alternative splicing results in diversification of mRNAs and finally of proteins, we need spliced mRNA isoform silencing to study the function of individual proteins. AsiDesigner is a web-based siRNA design software system, which provides siRNA design capability to account for alternative splicing in mRNA level gene silencing. It provides numerous novel functions, including designing common siRNAs for the silencing of more than two mRNAs simultaneously, a scoring scheme to evaluate the performance of designed siRNAs by adopting state-of-t...

  • Chemical Synthesis of 2′-O-Alkylated siRNAs

    Updated: 2010-03-11 12:39:05
    Chemical synthesis has been a major endeavor to create active siRNAs. The downregulation of mRNA by 21-mer double-stranded siRNAs can be improved by using modified nucleotides, especially 2′-O-alkylated ones. Besides the commercially available 2¢-O-methyl ribosides, 2′-alkyl groups bearing positive charges are especially promising candidates. We have shown that in a proper formulation they are superior to unmodified siRNAs. This may be due to enhanced stability and most probably to a better uptake into the cells. (Source: Springer protocols feed by Immunology)

  • Adjuvant Activity on Human Cells In Vitro

    Updated: 2010-02-19 12:39:06
    Efficient Vacciness against intracellular microbes or tumors will be based on innovative adjuvants able to induce efficient activation of dendritic cells. Indeed, natural or synthetic products activating Toll-like receptors (TLR) on dendritic cells (DCs) are currently in development for this purpose. Herein, we describe in vitro assays on human cells which might be useful for the preclinical screening and assessment of potential DC activators. (Source: Springer protocols feed by Immunology)

  • Nonclinical Safety Assessment of Vacciness and Adjuvants

    Updated: 2010-02-19 12:39:06
    To ensure the safe administration of Vacciness to humans, Vacciness (just like any new chemical entity) are evaluated in a series of nonclinical safety assessment studies that aim at identifying the potential toxicities associated with their administration. The nonclinical safety assessment of Vacciness, however, is only part of a testing battery performed prior to human administration, which includes (1) the evaluation of the Vaccines in efficacy and immunogenicity studies in animal models, (2) a quality control testing program, and (3) toxicology (nonclinical safety assessment) testing in relevant animal models. Although each of these evaluations plays a critical role in ensuring Vaccines safety, the nonclinical safety assessment is the most relevant to the evaluation in human clinical t...

  • Large-Animal Model for Establishing E/T Ratio of Adjuvants

    Updated: 2010-02-19 12:39:05
    To develop novel adjuvants for use in humans, the efficacy/toxicity (E/T) ratio of experimental products in large animal species can be investigated. The test model included two intramuscular immunizations in pigs at 3 weeks interval and analysis of immune responses and local reactions 1 week after the second injection. The antigen used to determine adjuvant activity was a well-defined, purified, viral glycoprotein that without adjuvant induces low immune responses and no detectable local reactions. Efficacy was determined by measuring ELISA and virus-neutralizing antibody titres. Toxicity was determined by necropsy and estimating size and severity of local reactions to each treatment. The persistence of the side effects was deduced from the difference in the local reaction 4 weeks after t...

  • Quantitative Multiparameter Assays to Measure the Effect of Adjuvants on Human Antigen-Specific CD8 T-Cell Responses

    Updated: 2010-02-19 12:39:05
    Large numbers and functionally competent T cells are required to protect from diseases for which antibody-based Vacciness have consistently failed (1), which is the case for many chronic viral infections and solid tumors. Therefore, therapeutic Vacciness aim at the induction of strong antigen-specific T-cell responses. Novel adjuvants have considerably improved the capacity of synthetic Vacciness to activate T cells, but more research is necessary to identify optimal compositions of potent Vaccines formulations. Consequently, there is a great need to develop accurate methods for the efficient identification of antigen-specific T cells and the assessment of their functional characteristics directly ex vivo. In this regard, hundreds of clinical vaccination trials have been implemented during...

  • Determining Adjuvant Activity on T-Cell Function In Vivo: Th Cells

    Updated: 2010-02-19 12:39:05
    Adjuvants constitute a critical component in Vaccines development in terms of both stimulating and directing immune responses of a suitable profile to promote protection against a diverse range of disease targets. In the past, the field of adjuvant research was mainly dominated by empirical testing and serendipity. However, there is a strong need to develop new generations of adjuvants based on rational design, as well as a requirement to characterise and comprehend their mechanism(s) of action. Adjuvant development can be characterised as an iterative process where potential candidates are repeatedly tested in vitro and in vivo for immunogenicity and optimised in terms of formulation and delivery. Novel lead candidates of adjuvants with a suitable immunological profile relative to specifi...

  • Functional Antibody Assays

    Updated: 2010-02-19 12:39:05
    Functional antibody assays can broadly be divided into three categories: neutralisation, serum bactericidal antibody (SBA) and opsonophagocytic assays (OPA). These biological assays are generally more complex than antibody-binding counterparts. They invariably involve multiple biological components, many of which are difficult or impossible to standardise. The aim of this chapter is to provide working examples of these assays and highlight the key issues to be addressed to ensure they are able to provide reliable data. (Source: Springer protocols feed by Immunology)

Current Feed Items | Previous Months Items

Feb 2010 | Jan 2010 | Dec 2009 | Nov 2009 | Oct 2009 | Sep 2009